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Chemokines are critical molecules in leukocyte traf-
¢cking, promoting site-speci¢c migration to various
tissues. The chemokine receptor CCR4 has recently
been associated with skin-homing T cells. In view of
the potential importance of CCR4 in skin homing of
T cells, we investigated the expression pattern of CCR4
and its ligands TARC/CCL17 and MDC/CCL22 in the
peripheral blood and skin of patients with cutaneous
T cell lymphoma, a putative malignancy of the
skin-homing T cells. In this study we analyzed the pat-
tern of coexpression of the skin-homing molecules
cutaneous lymphocyte antigen (CLA) and CCR4 in
the blood and skin of patients with cutaneous T cell
lymphoma. In the blood of cutaneous Tcell lymphoma
patients with peripheral blood involvement we found
signi¢cantly increased percentages of T cells displaying
the skin-homing phenotype (CLAþCCR4þ ) com-
pared with healthy individuals. T cells expressing CLA
and CCR4 were also found at high levels in cutaneous
T cell lymphoma lesions along with abundant expres-
sion of the two CCR4 ligands TARC/CCL17 and MDC/
CCL22. These data may explain, in part, why these T
cells accumulate in the skin, a diagnostic feature of cu-
taneous T cell lymphomas. Key words: CLA/mycosis fun-
goides/skin homing/T cell. J Invest Dermatol 119:1405 ^1410,
2002
C
utaneous T cell lymphomas (CTCL) are a subset of
extranodal non-Hodgkin’sTcell lymphomas that are
considered to be a malignancy of skin-homing
memory T cells (Robert and Kupper, 1999). In the
early stages of the disease (e.g., stage IA mycosis
fungoides), malignant clonal T cells are found almost exclusively
in the skin and usually can be detected in the circulation only
with highly sensitive polymerase chain reaction (PCR) based as-
says (Muche et al, 1997). A signi¢cant fraction of malignant lym-
phocytes in CTCL express the well-described skin-homing
receptor cutaneous lymphocyte antigen (CLA) (Picker et al,
1990), explaining in part the a⁄nity of these T cells for the skin
(Robert and Kupper, 1999).
It is widely believed that the ¢rst step in the process of T cell
extravasation to the skin is mediated via interaction of CLAwith
its ligand E-selectin expressed by endothelial cells. This selectin-
mediated step needs to be followed by chemokine signaling that
will eventually lead to integrin-mediated adhesion to the vessel
wall and ¢nally diapedesis across the vessel wall. A recent report
highlighted the crucial role of CCR4 in T cell homing to skin
(Campbell et al, 1999). This study demonstrated that the majority
of CLA-expressing T cells are CCR4þ .
The CCR4 ligand TARC (thymus and activation regulated
chemokine or CCL17) is capable of inducing integrin-dependent
adhesion of CLAþT cells to intracellular adhesion molecule 1
(ICAM-1) in vitro, and TARC/CCL17 is detected in skin post ca-
pillary venules. Based on these observations, extravasation of T
cells into skin is thought to be mediated via the sequential inter-
actions of CLAwith E-selectin, CCR4 with TARC/CCL17, and
leukocyte function antigen (LFA-1) with ICAM-1.
Although successful recruitment of T cells requires the combi-
natorial action of all three receptor ligand pairs, the components
are not regulated in the same fashion. In particular, ICAM-1 is
constitutively expressed by endothelial cells throughout the body,
including the skin. Levels can be increased in sites of skin in£am-
mation, but ICAM-1 is not thought to de¢ne tissue speci¢city
(Lewis et al, 1989). LFA-1, while critical for cell migration into tis-
sues, is also constitutively expressed by T cells, and although
memory cells express higher levels than do naive T cells, expres-
sion of LFA-1 similarly does not confer tissue speci¢city. In con-
trast, CLA and CCR4 are expressed on overlapping subsets of
memoryT cells and together may regulate skin-speci¢c homing.
Although CLA expression has been reported on CTCL cells
(Picker et al, 1990; Borowitz et al, 1993), and the level of CLA ex-
pression has been correlated with the extent of skin involvement
in CTCL patients (Borowitz et al, 1993; Heald et al, 1993), there are
no published reports on expression of CCR4 in these patients.
In this study we analyzed the expression of CLA and CCR4
on T cells in both skin and peripheral blood of patients with
CTCL. Our data show signi¢cantly increased percentages of
circulating ‘‘skin-homing’’ T cells coexpressing CLA and CCR4
in CTCL patients with peripheral blood involvement, com-
pared with healthy controls. We also report high levels of
CLAþCCR4þT cells, and abundant expression of the two
known CCR4 ligands TARC/CCL17 and MDC/CCL22, in
CTCL skin lesions.
MATERIALS ANDMETHODS
Patients and healthy donors Peripheral blood mononuclear cells were
isolated from heparinized venous blood obtained from biopsy proven
CTCL patients (n¼11) from the Cutaneous Oncology Clinic at the
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Dana-Farber Cancer Institute and healthy volunteers (n¼ 8) using density
gradient centrifugation over Ficoll (Histopaque, Sigma). All 11 patients had
peripheral blood involvement based on the criteria recently proposed by
Vonderheid et al (2002): a CD4/CD8 ratio greater than 10, percentage of T
cells with a CD4þCD7^phenotype 440%, evidence of a T cell clone in
the blood identi¢ed by southern blot or using antibodies to the T cell
receptor Vb chain (see Table IA). The age of the patients and donors
ranged between 51 and 92 and 33^61, respectively. Out of the 11 patients
10 were Caucasian, one Hispanic; all healthy controls were Caucasian. For
£ow cytometric analyses of skin lymphocytes, shave biopsies (E8 mm)
were obtained from the lesional skin of seven CTCL patients under local
lidocaine anesthesia (for clinical information and laboratory values see
Table IB), and four normal skin samples were obtained from patients
undergoing elective plastic surgery. For immunohistochemical analysis,
frozen tissue blocks from four cases of CTCL were retrieved from the
archives of the Department of Pathology, Brigham andWomen’s Hospital.
Frozen tissue was also obtained from three normal skin samples from
plastic surgery.
T cell analysis from normal skin and CTCL biopsies Skin samples
(normal and CTCL) were processed as previously described (Kunkel et al,
2000; Campbell et al, 2001). Brie£y, skin samples were cut into small pieces
and placed in 5 mM ethylenediamine tetraacetic acid at 41C for 4 h with
continuous gentle agitation. The resultant cell suspension was ¢ltered
through a nylon mesh ¢lter, washed with phosphate-bu¡ered saline, and
stained for £ow cytometry.
Monoclonal antibodies The following monoclonal antibodies were
used in this study: unlabeled CCR4 (clone1G1 from Millennium,
Cambridge, MA), goat F(ab0)2 antimouse IgG (Hþ L) PE (Southern
Biotech), CCR4 PE (clone 1G1 from Pharmingen), CD4 FITC
(Immunotech), CD7 FITC (Immunotech), CD8 FITC (Immunotech),
CD45RO FITC (Immunotech), CLA FITC (Pharmingen), CD3 PerCp
(Becton Dickinson). Isotype controls used were unlabeled IgG1 (Dako),
rat IgM FITC, IgG1 PE (Pharmingen), IgG2a FITC, IgG1 FITC
(Immunotech), and IgG1 PerCp (Becton Dickinson).
Flow cytometric analysis Three-color £ow cytometry was performed
by incubating 5105 cells (peripheral blood mononuclear cells) or 5104
cells (isolated from skin) with unlabeled monoclonal antibodies against
CCR4 followed by PE-goat antimouse IgG1, followed by the indicated
directly conjugated monoclonal antibodies. Alternatively, in some
experiments the directly conjugated form of the CCR4 antibody was
used. After staining, cells were ¢xed with 1% paraformaldehyde and
analyzed using a FACScan £ow cytometer (Becton Dickinson). CCR4
was analyzed on T cells isolated from both peripheral blood and skin
(CTCL and normal) by gating on the CD3þ population.
Immunohistochemical analysis Immunohistochemical studies were
performed on 5^6 mm frozen sections of normal skin obtained from
plastic surgery and lesional skin biopsies from CTCL patients (three stage
IB patients and one patient with stage III CTCL). TARC and macrophage-
derived chemokine (MDC) protein expression were determined using
anti-TARC (PeproTech) and anti-MDC (R&D Systems) antibodies,
respectively, and CCR4 expression was examined using anti-CCR4
monoclonal antibody (1G1 clone from Millennium). Following ¢xation
in cold 1% paraformaldehyde for 5 min or in cold acetone for 10 min,
sections were placed in 0.05 M Tris bu¡er, pH 7.6. Sequential sections
were incubated for 1 h with each of the monoclonal antibodies, washed,
and then incubated for 30 min with horseradish peroxidase conjugated
goat antimouse immunoglobulin (ImmunoVision Technologies, Daly
City, CA, or Dako, Carpinteria, CA). Antibody localization was
visualized using a peroxidase reaction with DAB as chromogen (Dako).
Slides were counterstained with methylene green solution, dehydrated,
and mounted with Polymount (Polysciences, Warrington, PA). A control
slide substituting Tris bu¡er for the primary antibody was run in all cases.
Statistical analyses CCR4 expression in the peripheral blood of CTCL
patients and healthy controls was compared using the Mann^Whitney U
test. Probability values of po0.05 were considered statistically signi¢cant.
Data are presented as mean7standard error of the mean (SEM).
RESULTS
To characterize the expression of CCR4 relative to other skin-
homing signals in CTCL, we examined expression patterns of
CCR4 and CLA on T cells, as well as the CCR4 ligands TARC
(CCL17) and MDC (CCL22), in skin from CTCL patients and
normal controls. All of the CTCL patients studied had peripheral
Table I Comparison of clinical parameters, laboratory values, and £ow cytometry data showing the expression of skin-homing
receptors on peripheral blood Tcells (A) and skin lesions (B) of CTCL patients. nThe highest recorded CD4/CD8 ratios are
shown. Analysis of the expression of skin-homing receptors onTcells from the peripheral blood and skin from the same patient
was done on three patients (Pt.# 2, 5, 10)
A. Comparison of clinical, laboratory data and £ow cytometry results on T cells from CTCL patients with peripheral blood involvement
Pt.# Sex/Age Stage/Dx Extent of skin involvement Evidence for peripheral blood involvementn CCR4þ CLAþCCR4þ
1 F/71 III/E-CTCL/SS Erythroderma CD4/CD8 ratio¼ 73; %CD4þCD7¼65% 45.7 8.2
2 F/51 IV/E-CTCL/SS Erythroderma CD4/CD8 ratio¼15;Vb14 clone¼ 81% 78 73.1
3 M/74 III/E-CTCL/SS Erythroderma CD4/CD8 ratio¼11 47.5 22.6
4 M/72 IB/MF Limited (o10% body surface) CD4/CD8 ratio¼15 31.5 15.4
5 M/51 III/ECTCL/SS Erythroderma CD4/CD8 ratio¼13; %CD4þCD7¼
59%;Vb18 clone¼ 94%
58 16
6 F/94 III/E-CTCL/SS Erythroderma CD4/CD8 ratio¼ 37; %CD4þCD7¼ 95%;
Vb2 clone¼ 96%
91.6 54
7 F/58 IV/E-CTCL/SS Erythroderma CD4/CD8 ratio¼ 21; %CD4þCD7¼66% 41.8 16
8 M/61 III/E-CTCL/SS Erythroderma T cell clone detected with Southern blot 75 10
9 M/68 IV/E-CTCL/SS Erythroderma %CD4þCD7¼ 77%;Vb5.1 clone¼ 73% 72.23 14.6
10 M/76 III/E-CTCL/SS Erythroderma CD4þCD8 ratio¼13;Vb20 clone¼ 94% 80 9
11 M/59 III/ECTCL/SS Erythroderma %CD4þCD7¼86% 59.6 49.6
B. Comparison of clinical, laboratory data and £ow cytometry results onT cells obtained from CTCL skin lesions
Pt.# Sex/Age Stage/Dx Extent of skin involvement Evidence for peripheral blood involvementn CCR4þ CLAþCCR4þ
2 F/51 III/E-CTCL/SS Erythroderma CD4/CD8 ratio¼15;Vb14 clone¼ 81% 78.5 49
5 M/51 III/E-CTCL/SS Erythroderma CD4/CD8 ratio¼13;Vb18 clone¼ 94% 84.5 39.2
10 M/76 III/E-CTCL/SS Erythroderma CD4/CD8 ratio¼13;Vb20 clone¼ 94% 95 45.3
12 M/65 IB/MF Patch/plaque (410% skin surface) none 39.2 24
13 M/74 IIB/MF Tumors none 81 74.3
14 M/70 IB/MF Tumors none 78.6 71.1
15 M/65 IIA/MF Patch/plaque (410% skin surface) none 87.2 73
nThe highest recorded CD4/CD8 ratios are shown
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blood involvement (see Table IA) as de¢ned by existing criteria
(see Materials and Methods).
T cells displaying the putative skin-homing phenotype
(CCR4 + CLA + ) are increased in the circulation of CTCL
patients versus healthy controls CCR4 expression on
circulating T cells was determined by £ow cytometry of
peripheral blood mononuclear cells isolated from normal
healthy volunteers (n¼ 8) and CTCL patients with peripheral
blood involvement (n¼11). Approximately 20% of peripheral
blood T cells (CD3þ gate) from healthy volunteers displayed
CCR4 (range 16.3%^24%; see Figs 1A, 2C, 3A). T cell CCR4
expression in the peripheral blood of CTCL patients was
signi¢cantly higher than in healthy donors, with an average of
62% (range 31%^92%, p¼ 0.0003) of CD3þ cells observed to
express CCR4 (see Fig 1A, 2C, 3B, C). As the age range of
normal blood donors (33^61 y) was younger than that of CTCL
patients (51^92 y), we examined CCR4 expression as a function
of age among normal subjects (Fig 1B). As no age-dependent
di¡erences in CCR4 expression were seen in the sample studied
this was unlikely to account for the expression patterns
observed.
Analysis of CLA expression on peripheral blood cells showed
that the percentage of CLAþ Tcells was also signi¢cantly higher
in CTCL patients (range 10%^92%) compared with healthy
controls (range 5.7%^15.7%) (average of 32% vs 10%,
respectively; p¼ 0.002) (see Figs 2C, 3A^C).
To assess coexpression of relevant surface epitopes, we
performed two- and three-color £ow cytometric analysis of
CCR4 expression on T cell subsets. Results were obtained and
are reported in three ways: (i) CCR4-expressing T cells were
characterized for their CD4, CD8, CD45RO, and CLA
phenotype (Fig 2A); (ii) T cell subsets (CD4þ , CD8þ ,
CD45ROþ, or CLAþ ) were characterized for the presence
and the extent of CCR4 expression (Fig 2B); and (iii) T cells
were examined for coexpression of CCR4 and CLA.
The majority of the T cells expressing CCR4 were found to
belong to the CD4þ subset in both normal controls (range
64.3%^94.7%, average 80%) and CTCL patients (range 28.4%^
99.4%; average 87%) (Fig 2A). A minority of CCR4þ T cells
in both groups expressed CD8þ , with the ratio of CD4þ to
CD8þ cells following the typical patterns observed in normal,
healthy controls. Signi¢cantly lower percentages of CCR4þ T
cells were found to belong to the CD8þ T cell population in
CTCL patients (range 3.8%^32%, average 9%), however,
compared to healthy controls (range 12%^47%, average 25%;
p¼ 0.01).
The majority of CCR4þ T cells in both CTCL patients and
normal controls were found to express CD45RO (average of
approximately 74% in both groups), indicating inclusion in the
memory T cell population. Approximately 30% of CCR4þ
cells expressed CLA in both CTCL patients (range 10%^97%)
Figure1. Flow cytometric analysis of CCR4 expression Peripheral
blood T cells from healthy individuals (n¼ 8) and CTCL patients (n¼11)
with peripheral blood involvement. (A) Symbols represent the individual
control and patient data points. The bar represents the mean of all points.
(B) CCR4 expression on T cells in correlation with the age of healthy
donors.
Figure 2. FACS analysis of CCR4 expression on peripheral blood T
cells from healthy controls and CTCL patients. (A) CCR4-expressing
T cells were analyzed for their phenotype. (B) T cell subsets were analyzed
for CCR4 expression and (C) expression of CCR4, CLA, and both on T
lymphocytes. The data are expressed as mean percent positive cells 7SEM.
Dotted bars represent results from healthy controls, closed bars from CTCL
patients. Stars represent signi¢cant di¡erences between CTCL patients and
healthy controls.
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and controls (range 20%^34.2%) (Fig 2A) indicating that
overlapping, but not identical, populations of cells bear these
two surface molecules.
Analysis of T cell subsets for CCR4 expression in healthy
individuals revealed that a minority of both CD4þ and
CD8þ T cell subsets displayed CCR4 (range 17.5%^56.2%,
average 28%, and range 16.5%^46.4%, average 33%, res-
pectively) (Fig 2B). In CTCL patients these percentages were
higher, with an average of 63% of CD4þ (range 27.6%^
92.4%) and an average of 56% of CD8þ T cells (range 36%^
71.4%) expressing CCR4. The di¡erence in CCR4 expression
by CD4þ T cells in CTCL patients versus normal controls was
signi¢cant (average 63% vs 28%, p¼ 0.004).
Approximately half of circulating memory (CD45ROþ ) T
cells expressed CCR4 in normal volunteers. In CTCL patients
relatively higher percentages of memory T cells were CCR4þ
compared to healthy controls (average 70%, range 50%^91.2%,
in CTCL patients versus average 42%, range 26.9%^59.1%, in
healthy controls, respectively; p¼ 0.06).
More importantly, in both patients and controls, a majority of
the CLAþ Tcells expressed CCR4 (average 79%, range 33.3%^
81.7%, and average 64%, range 51.8%^97%, respectively).
Consistent with these observations, three-color £ow
cytometry detected a signi¢cantly increased percentage of
CCR4þ CLAþ double-positive T cells in the peripheral blood
of CTCL patients (range 8.2%^73.1%) compared to healthy
volunteers (range 3.7%^6.2%) (average 26% vs 5.4%, po0.0001)
(Fig 2C). Fluorescence-activated cell sorter (FACS) pro¢les of T
cells (CD3þ gate) from a normal donor and two CTCL patients,
shown in Fig 3, highlight the massive shift seen in some
patients.
Among the criteria used for SeŁ zary syndrome, the leukemic
form of CTCL, is the observation of 440% of circulating T
cells displaying the SeŁ zary phenotype (CD4þ CD7^). To de¢ne
CCR4 expression in SeŁ zary syndrome, we analyzed expression
on CD7^ versus CD7þ T cell populations. Increased percentages
of Tcells with a CD4þ CD7^ phenotype (440% of total Tcell
population) were detected in six of the 11 patients included in this
study (see Table I). CCR4 expression in CTCL patients with
peripheral blood involvement but no increase in the percentage
of CD4þ CD7^ SeŁ zary cells was found mainly in the CD7þ
subset, a ¢nding that was similar to expression in healthy controls
(not shown). Analysis of CCR4 in the peripheral blood of six
CTCL patients with SeŁ zary syndrome showed that in most
patients the majority of CCR4 expression was seen on the
CD7^ T cell subset with a minority being CD7þ (average of
66% vs 34%). Interestingly, in two cases CCR4 expression was
seen primarily on the CD7þ T cell population (not shown).
Although individual cases showed dramatic di¡erences,
comparison of CCR4 expression between CD7þ and CD7^ T
cell subsets showed no signi¢cant di¡erences when all cases were
included.
Although expression of skin-homing receptors on circulating
T cells provides interesting insights into the progression of
CTCL, proof of the relevance of these features depends on
observations of T cells actually resident in lesional skin. To
characterize the role of these molecules in CTCL lesions and in
normal skin, £ow cytometry analysis of CCR4 and CLA
expression was performed onT cells isolated from skin.
CCR4 is expressed at high levels on T cells from both
normal skin and CTCL lesions T cells were isolated from
both normal skin (n¼ 4) and CTCL biopsies (n¼ 7) (see Table
IB) by nonenzymatic tissue disruption and analyzed using
three-color £ow cytometry, gating on the CD3þ population
(Fig 4). Both CLA and CCR4 were detected on the majority of
T cells isolated from both normal skin and CTCL lesions. CLA
was seen on a slightly higher percentage of T cells from lesional
skin compared to normal skin (average of 65% and 47%,
respectively; p¼ 0.06, not signi¢cant). CCR4 was seen on
closely similar percentages of T cells in CTCL lesions compared
to normal skin (average of 78% vs 63%, respectively). The
percentages of T cells coexpressing CLA and CCR4 in the
peripheral blood and lesions of CTCL patients included in this
study are displayed in Table IA and IB, respectively. In CTCL
patients the average percentage of CLAþ CCR4þ T cells in
the skin was signi¢cantly higher than that detected in the
peripheral blood (average of 54% vs 26%; p¼ 0.03).
CCR4 expression in normal and lesional skin was also
examined using immunohistochemistry (Fig 5). CCR4
immunoreactivity in normal skin was seen in association with
lymphocytes (found at low numbers) and dendritic cells, as well
as low-level expression in the basal layer of the epidermis
(Fig 5a). Increased epidermal CCR4 reactivity was seen in
CTCL lesions along with expression by large numbers of skin-
in¢ltrating lymphocytes and dendritic cells (Fig 5b).
TARC and MDC are constitutively expressed in normal skin
and are expressed more strongly in CTCL skin lesions To
analyze the expression of the two known CCR4 ligands and to
localize the expression of these chemokines in skin, frozen
sections from CTCL lesions and normal skin were examined
using immunohistochemical staining for TARC (CCL17) and
Figure 3. Expression of CCR4 and CLA on peripheral bloodTcells.
(A) Representative FACS plots of CCR4 expression and CLA and CCR4
coexpression on peripheral blood T cells (CD3 gate) in a healthy control
and (B, C) two CTCL patients with peripheral blood involvement. The
percentage of positive cells is indicated for each quadrant. Oval gate and
arrows showTcells coexpressing CLA and CCR4.
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MDC (CCL22). TARC immunoreactivity was found on dermal
endothelial cells in both normal skin and CTCL lesions, with
additional staining seen in association with the in¢ltrating
CTCL cells in lesional skin (Fig 5c, d). MDC immunostaining,
in contrast, was selectively localized to dendritic appearing cells
in both normal and CTCL skin (Fig 5e, f, respectively). In
normal skin, MDC immunostaining was seen predominantly in
the epidermal compartment, whereas in CTCL lesions it was seen
in association with increased numbers of dendritic cells in both
the epidermis and the dermis.
DISCUSSION
Identi¢cation of additional regulatory signals involved in T cell
homing to the skin, other than CLA, is fundamental to our un-
derstanding of immune-mediated skin diseases. Although it is
generally accepted that CLA is a marker for skin-homing T cells,
it is clearly only partially responsible for this complex process and
its ability to mediate leukocyte homing to the skin is dependent
on speci¢c chemokine receptor^ligand interactions.
Based on a recent report showing strong association between
skin-homing T cells and the chemokine receptor CCR4 (Camp-
bell et al, 1999), we characterized the expression pattern of CCR4
and its ligands (TARC and MDC) in CTCL, a malignancy of the
skin-homing T cells.
We found an increased percentage of T cells in the circulation
of CTCL patients with peripheral blood involvement displaying
the skin-homing (CLAþ CCR4þ ) phenotype, compared to
healthy, normal donors.We also demonstrated abundant expres-
sion of the CCR4 ligand TARC/CCL17 by endothelial cells in
CTCL lesions. These ¢ndings, together with the upregulation of
E-selectin and ICAM-1 seen in CTCL lesions (Fivenson et al,
1992; Uccini et al, 1993), indicate that the appropriate microenvir-
onment exists for extravasation of skin-homing T cells into
CTCL lesions. Indeed, analysis of T cells isolated directly from
skin revealed that a high percentage of T cells in CTCL lesions
display the same CLAþ CCR4þ skin-homing phenotype as
found in peripheral blood.
CCR4 expression has been previously reported on tumor cells
in lesions from mycosis fungoides, the most common form of
Figure 4. Flow cytometric analysis of CLA and CCR4 on the Tcell
population isolated from CTCL skin lesions and normal skin.Tcells
isolated from the skin were identi¢ed using CD3+ gate. (A) Representative
example of isotype control and CD3+ staining in normal skin. (B) CLA
and CCR4 analysis on T cells (CD3+ gate) isolated from normal skin in
comparison with (C) CLA and CCR4 expression onT cells from a CTCL
lesion and (D) the matching isotype control staining of skin cells from the
same CTCL patient. Note the very high percentages of T cells expressing
CLA and CCR4 in normal skin and at a higher level in the CTCL lesion.
Figure 5. CCR4,TARC and MDC immunostaining in the skin. Re-
presentative tissue sections showing (A) CCR4 immunoreactivity in nor-
mal skin (a) and CTCL lesion (b) in association with mononuclear cells; (B)
TARC/CCL17 immunoreactivity localized to endothelial cells in both nor-
mal skin and CTCL lesions (c, d) and (C) MDC/CCL22 immunostaining
by cells with dendritic morphology in normal skin and CTCL lesions
(e, f ).
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CTCL, and in patients with nodal large cell transformation (Jones
et al, 2000). In addition, we identi¢ed TARC immunoreactivity
in the epidermis, as well as endothelial cells, of CTCL lesions.
This ¢nding, along with a recent report showing TARC expres-
sion by keratinocytes during in£ammation (Vestergaard et al,
2000), suggests that the role of this chemokine may extend be-
yond transendothelial diapedesis. TARC may also contribute to
the epidermotropism, or accumulation of malignant T cells in
the epidermis, seen as a hallmark feature of early CTCL. A role
for CCR4 interactions withTARC/CCL17 in the pathogenesis of
immune-mediated skin diseases is also suggested by reports
showing increased CCR4 andTARC expression in atopic derma-
titis patients (Vestergaard et al, 2000) and increased CCR4 expres-
sion in psoriasis lesions (Rottman et al, 2001).
The other known CCR4 ligand, MDC/CCL22, was predomi-
nantly localized to dendritic cells found in increased numbers in
both epidermal and dermal compartments (Langerhans cells and
dermal dendritic cells, respectively) in CTCL lesions, suggesting
that MDC/CCL22 production by these dendritic cells may have a
role in positioning malignant T cells to the epidermis or dermis.
Recent reports in the literature show that MDC is induced in ac-
tivated dendritic cells (Soumelis et al, 2002) and it may play a role
in the formation of dendritic cell^T cell clusters in the skin (Ka-
tou et al, 2001). Our data along with these observations suggest
that strong MDC/CCL22 expression by Langerhans cells in the
epidermis may be involved in the aggregation of CCR4þ ma-
lignant T cells in the skin, leading to the development of Pau-
trier’s microabscesses, or clusters of neoplastic lymphoid cells,
that are characteristic of mycosis fungoides. A similar pheno-
menon has been described in Hodgkin’s disease, in which
Reed^Sternberg cells were shown to produce TARC/CCL17,
thereby attracting CCR4-expressing cells and forming the char-
acteristic in£ammatory in¢ltrate in this disease (van den Berg
et al, 1999).We also show that the mononuclear cells in¢ltrating
CTCL lesions become additional sources of TARC/CCL17,
which could lead to further recruitment of CCR4-expressing T
cells and ampli¢cation of the in£ammatory response. In conclu-
sion, we show an increased percentage of T cells displaying the
skin-homing phenotype (CLAþ CCR4þ ) in the circulation
and skin of CTCL patients along with abundant expression of
the CCR4 ligands TARC/CCL17 and MDC/CCL22 in CTCL
skin, strongly suggesting the involvement of the CCR4^TARC/
CCL17, MDC/CCL22 pathway in recruitment of CLAþ
CCR4þ T cells to CTCL skin. These results may explain why
these T cells have such strong a⁄nity for the skin ^ a diagnostic
feature of CTCL. Due to the potential pathophysiologic signi¢-
cance of CCR4 and its ligands in T cell homing to the skin,
CCR4 may serve as a therapeutic target in CTCL patients.
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